

Which cholinesterase inhibitor for early dementia?

Consider drug differences, patient factors
to find a good match

Sanjeev M. Kamat, MD

Fellow in geriatric psychiatry

George T. Grossberg, MD

Samuel W. Fordyce Professor

Philip J. LeFevre, MD

Associate professor

Department of psychiatry
Saint Louis University School of Medicine
St. Louis, MO

Using a cholinesterase inhibitor (ChEI) makes sense for any disorder with a significant cholinergic deficit, such as Alzheimer's disease (AD) and other forms of mild-to-moderate dementia (Box 1, page 56).¹⁻³ Yet the ChEIs tacrine, donepezil, rivastigmine, and galantamine have pharmacologic differences, and individual patients respond differently to them.

To help you choose the safest, most effective treatment for each patient, we discuss:

- three cases that show how ChEIs differ in mechanism of action, administration, and side effects
- evidence of ChEIs' efficacy in AD—for



© Michael Prince / CORBIS



Box 1

Is it Alzheimer's? One-third of dementias are something else

Probable Alzheimer's disease (AD) accounts for 64% of all dementias in the United States. Less-common causes include:

- vascular dementia (5%)
- combined vascular dementia and AD (10%)
- probable dementia with Lewy bodies, Parkinson's dementia, or diffuse Lewy body disease (9%)
- Lewy body variant of AD, or AD and dementia with Lewy bodies (6%)
- frontotemporal dementia, corticobasal degeneration, progressive supranuclear palsy, or Creutzfeldt-Jakob disease (6%).^{2,3}

In our experience, many primary care physicians choose to follow their patients with dementia, even when clinical features are atypical or suggest unusual causes. Psychiatrists are asked most often to assist in diagnosis and management of patients with:

- uncommon dementias, including frontotemporal dementia or dementia with Lewy bodies
- rapidly progressive dementia
- dementia in a patient age <60
- dementia with psychiatric comorbidities or severe behavior disturbances.⁴

which they are approved—and in other dementias for which they have been tried

- when to switch agents, and how long to continue treatment.

HOW ChEIs DIFFER

Although dementia remains incurable, recognizing cognitive decline early allows you to start ChEI therapy before substantial neuronal loss occurs (Box 2, page 57).^{3,4} The goal of early treatment is to improve or stabilize cognition, behavior, and activities of daily living for as long as possible.

In comparison studies,^{5,6} ChEIs have shown differences in tolerability but not consistent differences in efficacy for mild to moderate AD—though

these studies had methodologic limitations. Because the agents appear similarly effective, the initial ChEI choice often depends on how their differences might benefit your patient (Table 1, page 58). Consider the following cases:

CASE 1: GRADUAL MEMORY LOSS

Mrs. J, age 76, has experienced a slow, insidious memory decline across 5 years. She has become socially withdrawn and shows some language difficulties. She has had peptic ulcer disease and often does not take medications as prescribed.

Her psychiatrist diagnoses probable AD and chooses donepezil with its easy dosing schedule because of Mrs. J's history of nonadherence. Donepezil's GI tolerability is also a factor in this choice because of the patient's peptic ulcer disease.

CASE 2: DEMENTIA AND MOTOR DEFICITS

Mr. L, age 82, has gradually developed memory loss and parkinsonian symptoms, including slowness of movement and shuffling gait. He has visual hallucinations of people and episodic confusion. His med-

ications include warfarin and digoxin for atrial fibrillation and congestive heart failure.

Mr. L is diagnosed with probable dementia with Lewy bodies. His psychiatrist chooses rivastigmine because it has shown efficacy in this type of dementia and is not known to interact significantly with cardiovascular medications.

CASE 3: STROKE, THEN RAPID DECLINE

Mrs. D, age 68, has a history of hypertension and suffered a stroke in the past. Her family says her memory and behavior—anger outbursts and excessive irritability—have worsened rapidly across 2 years. Examination reveals some focal neurologic deficits.

Her psychiatrist diagnoses probable vascular

dementia and chooses galantamine for its efficacy in patients with this dementia type. Mrs. D has no history of GI illness and will likely tolerate the drug's GI side effects. Follow-up care will include monitoring for tolerability.

Mechanism. Donepezil inhibits the enzyme acetylcholinesterase, and rivastigmine inhibits acetylcholinesterase and butyrylcholinesterase. Galantamine inhibits acetylcholinesterase and shows allosteric modulation of the presynaptic nicotinic receptor.

Data indicating that rivastigmine is particularly effective in patients with rapidly progressive illness is consistent with the possible advantage of inhibiting both butyrylcholinesterase and acetylcholinesterase. It has been argued that galantamine's binding to nicotinic receptors modulates their function, which may enhance acetylcholine release.

Among the three agents, only rivastigmine shows a consistent, linear dose-response relationship. It is rapidly and extensively metabolized, primarily via cholinesterase-mediated hydrolysis to the decarbamylated metabolite (autohydrolysis). Minimal metabolism occurs via the major cytochrome P (CYP)-450 isoenzymes. Donepezil and galantamine are metabolized by isoenzymes 2D6 and 3A4 and undergo glucuronidation.⁷

Drug interactions. Because rivastigmine avoids hepatic metabolism, interactions with drugs metabolized by CYP-450 isoenzymes have not been reported.⁸

Donepezil interacts with ketoconazole and quinidine, which inhibit donepezil metabolism and increase mean donepezil concentrations. Galantamine interacts with ketoconazole, paroxetine, and erythromycin, which increase mean galantamine concentrations.⁹

Box 2

Dementia diagnosis: Earlier is better

An early dementia diagnosis enables you educate the patient and family (Box 3, page 67) and begin the most effective treatment for the person with cognitive decline. Although dementia remains incurable, early recognition presents the opportunity to start cholinesterase inhibitors before substantial neuronal loss occurs.^{3,4}

Patient workup. The Alzheimer's Association offers online information for health care professionals on AD diagnosis and treatment protocols (see Related resources, page 67). A detailed history, physical examination, and Mini-Mental State Examination (MMSE) are necessary if you suspect Alzheimer's or a related dementia.

Also recommended are a comprehensive metabolic screen, complete blood counts with differential, urine analysis, serum B12 and folate studies, homocysteine levels, thyroid studies, chest radiography, ECG, lipid profile, and brain scan (MRI or CT). Perform studies such as the rapid plasma reagin test for syphilis and HIV testing as appropriate.

Administration. Donepezil and extended-release galantamine are given once daily because of their long half-lives, whereas regular galantamine and rivastigmine are taken twice daily with meals to minimize GI effects (Table 2, page 61). Nausea and vomiting can occur with any of the ChEIs but are more common and troublesome with rivastigmine and galantamine.

EFFICACY IN EARLY AD

In controlled clinical trials, all four ChEIs have significantly improved cognition, behavior, and activities of daily living in patients with mild-to-moderate AD.¹⁰⁻¹² Tacrine—the first FDA-approved ChEI—is rarely used because its associated hepatotoxicity requires ongoing liver enzyme monitoring.¹³ Among the other three:

Donepezil. A review of 16 trials involving 4,365 par-



Table 1
Similarities and differences among cholinesterase inhibitors

	Tacrine	Donepezil	Rivastigmine	Galantamine
Administration	Four times daily	Once daily	Twice daily with full meals	Once daily (extended-release formulation)
AChE inhibitor	Yes	Yes	Yes	Yes
BuChE inhibitor	Yes	No	Yes	No
Allosteric modulation of nicotinic receptor	No	Yes	No	Yes
Pharmacodynamic nicotinic/muscarinic effect	Yes	Yes	Yes	Yes
GI side effects	Present	Present	Present	Present
Hepatotoxicity	Present	Absent	Absent	Absent
Metabolism	CYP-450	CYP-450	Autohydrolysis	CYP-450
Drug–drug interactions	Yes	Yes	None reported	Yes

AChE: acetylcholinesterase
BuChE: butyrylcholinesterase
CYP-450: cytochrome P-450 hepatic isoenzymes

ticipants¹⁰ found significant benefits in cognitive functioning, activities of daily living, and behavior in persons with mild, moderate, or severe AD who were treated with donepezil for 12, 24, or 52 weeks.

Rivastigmine improved or maintained cognitive function, activities of daily living, and behavior for up to 52 weeks in patients with mild to moderate AD, according to a review of studies from 1995 to 2002.¹¹ GI irritation was the most common adverse effect. Giving rivastigmine for up to 2 years may reduce the cost of caring for patients with AD, mostly by delaying nursing home placement.

Galantamine has beneficial effects on cognition, global function, activities of daily living, and behavior in patients with AD, vascular dementia, and AD with cerebrovascular components,

according to a review of clinical studies.¹² Adverse events are generally mild to moderate, transient, and gastrointestinal.

EFFICACY IN OTHER DEMENTIAS

In addition to their FDA-approved use for mild-to-moderate AD, ChEIs also have been studied in persons with other types of dementia and mild cognitive impairment (MCI).

Dementia with Lewy bodies. Rivastigmine given with flexible titration from 6 to 12 mg/d improved behavior in 120 patients with Lewy body dementia.¹⁴ In the double-blind, multicenter study, patients taking rivastigmine, mean 9.7 mg/d for 20 weeks, were less apathetic and anxious and had fewer delusions and hallucinations than did those

continued on page 61

continued from page 58

Table 2

How to use cholinesterase inhibitors for patients with dementia

Drug	Recommended dosing	Possible side effects	Titration	Administration
Tacrine	Initial: 40 mg/d Maximum: 160 mg/d	Liver damage causing increase in ALT levels, GI effects (nausea, indigestion, vomiting, diarrhea, abdominal pain), skin rash	Dosage can be increased every 4 weeks	Divide into four doses; take on empty stomach
Donepezil	Initial: 5 mg/d Maximum: 10 mg/d	GI effects (nausea, diarrhea, vomiting, loss of appetite), insomnia, muscle cramps, fatigue	Increase dosage after 4 weeks	Once daily in morning or at bedtime
Rivastigmine	Initial: 3 mg/d Maximum: 12 mg/d	GI effects (nausea, vomiting, loss of appetite, weight loss, diarrhea, heartburn)	Increase dosage every 4 weeks	Twice daily after meals
Galantamine (regular, ER)	Initial: 8 mg/d Maximum: 24 mg/d	GI effects (nausea, vomiting, diarrhea, weight loss), possible increased mortality risk in patients with MCI	Increase dosage every 4 weeks	Regular: Twice daily after meals ER: Once daily after a meal

ALT: alanine transferase
ER: extended-release formulation
MCI: mild cognitive impairment

taking placebo. The drug was judged to be safe and well tolerated.

Vascular dementia. Patients with vascular dementia showed improved cognition and global function when treated with donepezil, 5 or 10 mg/d, for up to 24 weeks. Donepezil was well tolerated in this combined analysis of two randomized, placebo-controlled trials.¹⁵

Kumar et al¹⁶ compared two rivastigmine dosages in patients with mild-to-moderate AD, some of whom also had vascular dementia risk factors. Patients were randomly assigned to placebo, low-dose rivastigmine (1 to 4 mg/d), or high-dose rivastigmine (6 to 12 mg/d) for 26 weeks. Cognition, activities of daily living, and disease

severity improved with rivastigmine in patients with or without vascular risk factors. Greater benefit was seen with high-dose than low-dose rivastigmine and in patients with AD plus vascular risk factors than in those with AD alone.

In a multicenter, double-blind trial,¹⁷ patients with vascular dementia or AD with vascular risk factors received galantamine, up to 24 mg/d, or placebo for 6 months. Compared with controls, those taking galantamine showed improved cognition, behavior, and function. The drug overall was well tolerated, with nausea and vomiting the most common side effects.

Parkinson's dementia. Emre et al¹⁸ evaluated rivastigmine's efficacy and safety in patients whose



Box 3

Information for patients and families about cholinesterase inhibitors

- Cholinesterase inhibitors may help improve or stabilize cognition, behavior, and/or activities of daily living
- Persons receiving these agents may decline more slowly than those who have not been treated
- Common side effects include nausea, vomiting, diarrhea, and loss of appetite
- Other less-common side effects are muscle cramps, slowed heart rate, dizziness, and fainting
- Because of differences in these agents, it may make sense to switch to another cholinesterase inhibitor if the patient has intolerable side effects or does not improve with the first one tried

mild-to-moderate dementia developed at least 2 years after a clinical diagnosis of Parkinson's disease (PD). Patients were randomly assigned to placebo or rivastigmine, 3 to 12 mg/d, for 24 weeks, and 410 of 541 enrollees completed the study. Compared with placebo, rivastigmine was associated with statistically significant improvements in cognition and global measures in dementia associated with PD but also with higher rates of nausea, vomiting, and tremor. PD's motor symptoms did not change significantly in either group.

Mixed dementia states. As mentioned, galantamine improved cognitive and noncognitive abilities in patients with vascular dementia or AD with vascular risk factors in a 6-month, double-blind trial.¹⁷ Patients who received galantamine or placebo could then continue open-label galantamine, 24 mg/d, for another 6 months. In patients treated the full 12 months, galantamine continued to improve or maintain:

- cognition, based on Alzheimer's Disease Assessment Scale-cognitive subscale scores
- functional ability, measured by the 40-item Disability Assessment for Dementia

- behavior, measured by the Neuropsychiatric Inventory.¹⁹

Frontotemporal dementia. No placebo-controlled trials have evaluated cholinesterase inhibitors in patients with frontotemporal dementia, although an open-label trial suggests that rivastigmine may benefit these patients and their caregivers. Moretti et al²⁰ used rivastigmine, 3 to 9 mg/d, in 20 patients ages 60 to 75 with probable frontotemporal dementia. A group of matched patients received antipsychotics, benzodiazepines, or selegiline.

After 12 months, the rivastigmine-treated patients were less behaviorally impaired than the matched patients, and their caregivers reported reduced stress. Rivastigmine did not prevent cognitive deterioration, as assessed with the Mini-Mental State Examination (MMSE).

Mild cognitive impairment. Persons with MCI have objective psychometric evidence of memory loss compared with their peers, but they are not significantly impaired in activities of daily living or other cognitive functions (language, abstract thinking, or problem-solving).

At this time, we do not recommend using ChEIs to treat MCI. These agents have shown little benefit and potential risk in patients who do not meet diagnostic criteria for dementia:

- Salloway et al²¹ tested donepezil's efficacy and safety in 270 patients with MCI in a 24-week, double-blind, placebo-controlled trial. Donepezil was started at 5 mg/d for 42 days, then escalated to 10 mg/d. Compared with placebo, donepezil showed no significant effects on recall, but some improvements were seen in attention and psychomotor speed.

- In two unpublished placebo-controlled trials, galantamine did not improve memory when given for 2 years to elderly patients with MCI. A

continued on page 67

Dose Dependency of Adverse Events in Short-Term, Placebo-Controlled Trials—Extrapyramidal Symptoms—In an acute-phase controlled clinical trial in schizophrenia, there was no significant difference in ratings scales incidence between any dose of oral olanzapine (5+2.5, 10+2.5, or 15+2.5 mg/d) and placebo for parkinsonism (Simpson-Angus Scale total score >3) or akathisia (Barnes Akathisia global score ≥2). In the same trial, only akathisia events (spontaneously reported COSTART terms akathisia and hyperkinesia) showed a statistically significantly greater adverse events incidence with the 2 higher doses of olanzapine than with placebo. The incidence of patients reporting any extrapyramidal event was significantly greater than placebo only with the highest dose of oral olanzapine (15+2.5 mg/d). In controlled clinical trials of intramuscular olanzapine for injection, there were no statistically significant differences from placebo in occurrence of any treatment-emergent extrapyramidal symptoms, assessed by either rating scales incidence or spontaneously reported adverse events.

Other Adverse Events—Dose-relatedness of adverse events was assessed using data from a clinical trial involving 3 fixed oral dosage ranges compared with placebo. The following treatment-emergent events showed a statistically significant trend: asthenia, dry mouth, nausea, somnolence, tremor.

Vital Sign Changes—Oral olanzapine was associated with orthostatic hypotension and tachycardia in clinical trials. Intramuscular olanzapine for injection was associated with bradycardia, hypotension, and tachycardia in clinical trials (see PRECAUTIONS).

Weight Gain—In placebo-controlled 6-week schizophrenia studies, weight gain was reported in 5.6% of oral olanzapine patients (average 2.8-kg gain) compared to 0.8% of placebo patients (average 0.4-kg loss); 29% of olanzapine patients gained >7% of their baseline weight, compared to 3% of placebo patients. During continuation therapy (238 median days of exposure), 56% of patients met the criterion for having gained >7% of their baseline weight. Average gain during long-term therapy was 5.4 kg.

Laboratory Changes—Olanzapine is associated with asymptomatic increases in SGPT, SGOT, and GGT and with increases in serum prolactin and CPK (see PRECAUTIONS). Asymptomatic elevation of eosinophils was reported in 0.3% of olanzapine patients in premarketing trials. There was no indication of a risk of clinically significant neutropenia associated with olanzapine in the premarketing database.

In clinical trials among olanzapine-treated patients with baseline random triglyceride levels of <150 mg/dL (N=485), 0.6% experienced triglyceride levels of ≥500 mg/dL anytime during the trials. In these same trials, olanzapine-treated patients (N=962) had a mean triglyceride increase of 27 mg/dL from a mean baseline of 185 mg/dL. In placebo-controlled trials, olanzapine-treated patients with baseline random cholesterol levels of <200 mg/dL (N=1439) experienced cholesterol levels of ≥240 mg/dL anytime during the trials significantly more often than placebo-treated patients (N=836; 8.1% vs 3.8% respectively). In these same trials, olanzapine-treated patients (N=2528) had a mean increase of 1 mg/dL in cholesterol from a mean baseline of 203 mg/dL, which was significantly different compared to placebo-treated patients (N=1420) with a mean decrease of 4 mg/dL from a mean baseline of 203 mg/dL.

ECG Changes—Analyses of pooled placebo-controlled trials revealed no statistically significant olanzapine/placebo differences in incidence of potentially important changes in ECG parameters, including QT, QTc, and PR intervals. Olanzapine was associated with a mean increase in heart rate of 2.4 BPM compared to no change among placebo patients.

Other Adverse Events Observed During Clinical Trials—The following treatment-emergent events were reported with oral olanzapine at multiple doses ≥1 mg/d in clinical trials (8661 patients, 4165 patient-years of exposure). This list may not include events previously listed elsewhere in labeling, those events for which a drug cause was remote, those terms which were so general as to be uninformative, and those events reported only once or twice which did not have a substantial probability of being acutely life-threatening. *Frequent* events occurred in ≥1/100 patients; *infrequent* events occurred in 1/100 to 1/1000 patients; *rare* events occurred in <1/1000 patients. **Body as a Whole**—*Frequent*: dental pain, flu syndrome; *Infrequent*: abdomen enlarged, chills, face edema, intentional injury, malaise, moniliasis, neck pain, neck rigidity, pelvic pain, photosensitivity reaction, suicide attempt; *Rare*: chills and fever, hangover effect, sudden death. **Cardiovascular**—*Frequent*: hypotension; *Infrequent*: atrial fibrillation, bradycardia, cerebrovascular accident, congestive heart failure, heart arrest, hemorrhage, migraine, pallor, palpitation, vasodilatation, ventricular extrasystoles; *Rare*: arteritis, heart failure, pulmonary embolus. **Digestive**—*Frequent*: flatulence, increased salivation, thirst; *Infrequent*: dysphagia, esophagitis, fecal impaction, fecal incontinence, gastritis, gastroenteritis, gingivitis, hepatitis, melena, mouth ulceration, nausea and vomiting, oral moniliasis, periodontal abscess, rectal hemorrhage, stomatitis, tongue edema, tooth caries; *Rare*: aphthous stomatitis, enteritis, eructation, esophageal ulcer, glossitis, ileus, intestinal obstruction, liver fatty deposit, tongue discoloration. **Endocrine**—*Infrequent*: diabetes mellitus; *Rare*: diabetic acidosis, goiter. **Hemic and Lymphatic**—*Infrequent*: anemia, cyanosis, leukocytosis, leukopenia, lymphadenopathy, thrombocytopenia; *Rare*: normocytic anemia, thrombocythemia. **Metabolic and Nutritional**—*Infrequent*: acidosis, alkaline phosphatase increased, bilirubinemia, dehydration, hypercholesteremia, hyperglycemia, hyperlipemia, hyperuricemia, hypoglycemia, hypokalemia, hyponatremia, lower extremity edema, upper extremity edema; *Rare*: gout, hyperkalemia, hypernatremia, hypoproteinemia, ketosis, water intoxication. **Musculoskeletal**—*Frequent*: joint stiffness, twitching; *Infrequent*: arthritis, arthrosis, leg cramps, myasthenia; *Rare*: bone pain, bursitis, myopathy, osteoporosis, rheumatoid arthritis. **Nervous System**—*Frequent*: abnormal dreams, amnesia, delusions, emotional lability, euphoria, manic reaction, paresthesia, schizophrenic reaction; *Infrequent*: akinesia, alcohol misuse, antisocial reaction, ataxia, CNS stimulation, cogwheel rigidity, delirium, dementia, depersonalization, dysarthria, facial paralysis, hypesthesia, hypokinesia, hypotonia, incoordination, libido decreased, libido increased, obsessive compulsive symptoms, phobias, somatization, stimulant misuse, stupor, stuttering, tardive dyskinesia, vertigo, withdrawal syndrome; *Rare*: circumoral paresthesia, coma, encephalopathy, neuralgia, neuropathy, nystagmus, paralysis, subarachnoid hemorrhage, tobacco misuse. **Respiratory**—*Frequent*: dyspnea; *Infrequent*: apnea, asthma, epistaxis, hemoptysis, hyperventilation, hypoxia, laryngitis, voice alteration; *Rare*: atelectasis, hiccup, hypoventilation, lung edema, stridor. **Skin and Appendages**—*Frequent*: sweating; *Infrequent*: alopecia, contact dermatitis, dry skin, eczema, maculopapular rash, pruritus, seborrhea, skin discoloration, skin ulcer, urticaria, vesiculobullous rash; *Rare*: hirsutism, pustular rash. **Special Senses**—*Frequent*: conjunctivitis; *Infrequent*: abnormality of accommodation, blepharitis, cataract, deafness, diplopia, dry eyes, ear pain, eye hemorrhage, eye inflammation, eye pain, ocular muscle abnormality, taste perversion, tinnitus; *Rare*: corneal lesion, glaucoma, keratoconjunctivitis, macular hypopigmentation, miosis, mydriasis, pigment deposits lens. **Urogenital**—*Frequent*: vaginitis*; *Infrequent*: abnormal ejaculation,* amenorrhea,* breast pain, cystitis, decreased menstruation,* dysuria, female lactation,* glycosuria, gynecomastia, hematuria, impotence,* increased menstruation,* menorrhagia,* metrorrhagia,* polyuria, premenstrual syndrome,* pyuria, urinary frequency, urinary retention, urinary urgency, urination impaired, uterine fibroids enlarged,* vaginal hemorrhage*; *Rare*: albuminuria, breast enlargement, mastitis, oliguria. (*Adjusted for gender.)

The following treatment-emergent events were reported with intramuscular olanzapine for injection at one or more doses ≥2.5 mg/injection in clinical trials (722 patients). This list may not include events previously listed elsewhere in labeling, those events for which a drug cause was remote, those terms which were so general as to be uninformative, and those events reported only once or twice which did not have a substantial probability of being acutely life-threatening. **Body as a Whole**—*Frequent*: injection site pain; *Infrequent*: abdominal pain, fever. **Cardiovascular**—*Infrequent*: AV block, heart block, syncope. **Digestive**—*Infrequent*: diarrhea, nausea. **Hemic and Lymphatic**—*Infrequent*: anemia. **Metabolic and Nutritional**—*Infrequent*: creatine phosphokinase increased, dehydration, hyperkalemia. **Musculoskeletal**—*Infrequent*: twitching. **Nervous System**—*Infrequent*: abnormal gait, akathisia, articulation impairment, confusion, emotional lability. **Skin and Appendages**—*Infrequent*: sweating.


Postintroduction Reports—Reported since market introduction and temporally (not necessarily causally) related to olanzapine therapy: allergic reaction (eg, anaphylactoid reaction, angioedema, pruritus or urticaria), diabetic coma, pancreatitis, priapism, rhabdomyolysis, and venous thromboembolic events (including pulmonary embolism and deep venous thrombosis). Random cholesterol levels of ≥240 mg/dL and random triglyceride levels of ≥1000 mg/dL have been rarely reported.

DRUG ABUSE AND DEPENDENCE: Olanzapine is not a controlled substance.

ZYPREXA is a registered trademark of Eli Lilly and Company. ZYDIS is a registered trademark of Cardinal Health, Inc. or one of its subsidiaries.

Literature revised April 14, 2005

PV3518 AMP

 Eli Lilly and Company
Indianapolis, IN 46285, USA

www.ZYPREXA.com

ZYPREXA® (Olanzapine Tablets)
ZYPREXA® ZYDIS® (Olanzapine Orally Disintegrating Tablets)
ZYPREXA® IntraMuscular (Olanzapine for Injection)

continued from page 62

Related resources

- ▶ Alzheimer’s Association. Information for health care professionals:
 - Diagnosing Alzheimer’s
www.alz.org/Health/Diagnose/overview.asp
 - Treating cognitive symptoms
www.alz.org/Health/Treating/symptoms.asp
- ▶ American Association for Geriatric Psychiatry. Information for older patients and their families on Alzheimer’s disease, other dementias.
www.gmhfonline.org/gmhf/consumer/alzheimers.html.

DRUG BRAND NAMES

Tacrine • Cognex
Donepezil • Aricept
Rivastigmine • Exelon
Galantamine • Razadyne (was Reminyl)

DISCLOSURES

Drs. Kamat and LeFevre report no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.

Dr. Grossberg receives grant/research support from Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals, Cyberonics, Eli Lilly and Co., Eunoe, Forest Pharmaceuticals, Novartis Pharmaceuticals Corp., Pfizer, and Wyeth Pharmaceuticals. He is a consultant to AstraZeneca Pharmaceuticals, Forest Pharmaceuticals, Janssen Pharmaceutica, KV Pharma, Novartis Pharmaceuticals Corp., Organon International, and Sanofi-Synthelabo.

ACKNOWLEDGMENT

The authors thank Anjali Baliga, MD, for her contribution and help in preparing this article

precaution was added to the drug’s prescribing information because 13 of the 1,026 patients taking galantamine died, compared with 1 of 1,022 taking placebo. Vascular disease caused one-half of the galantamine group deaths. No evidence of increased mortality risk has been seen in studies of galantamine in patients with mild-to-moderate AD, for which it is indicated.

GETTING THE GREATEST RESPONSE

To gauge response to ChEI therapy, family reports about the patient are helpful—such as that cognition has improved or cognitive decline has not progressed as rapidly as before. Assessment tools such as the MMSE can document improvement or stabilization.

We recommend trying an initial ChEI for at least 6 months to determine its efficacy. If your



patient cannot tolerate one ChEI or fails to respond to initial treatment, two consensus panels^{22,23} recommend that you consider changing ChEIs:

- If switching because of intolerable side effects, wait at least 2 to 3 days after stopping the first ChEI before starting another.
- If switching because of poor response, you can start a different ChEI immediately after the first one is stopped.

Long-term therapy. If ChEI therapy is effective and well tolerated, encourage patients and their families to continue it indefinitely (Box 3, page 62). Withdraw the medication when the patient progresses to dementia's terminal phases and no longer has a meaningful quality of life.

References

1. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. *JAMA* 1997; 278(16):1363-71.
2. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. *Neurologic Diseases in the Elderly Research Group. Neurology* 2000;54(11 suppl 5):S4-S9.
3. Grossberg GT, Lake JT. The role of the psychiatrist in Alzheimer's disease. *J Clin Psychiatry* 1998;59(suppl 9):3-6.
4. Doraiswamy PM, Steffens DC, Pitchumoni S, Tabrizi S. Early recognition of Alzheimer's disease: what is consensual? What is controversial? What is practical? *J Clin Psychiatry* 1998;59(suppl 13):6-18.

5. Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. *Int J Clin Pract* 2002;56(6):441-6.
6. Jones RW, Soiminen H, Hager K, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. *Int J Geriatr Psychiatry* 2004;19(1):58-67.
7. Grossberg GT, Stahelin HB, Messina JC, et al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. *Int J Geriatr Psychiatry* 2000;15(3):242-7.
8. U.S. Bureau of the Census. 2004 International database: Midyear population, by age and sex. Table 094. U.S. Bureau of the Census; 2004.
9. Reminyl (galantamine HBr). Physicians' desk reference (59th ed). Montvale, NJ: Thomson PDR; 2005:1739.
10. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. *Cochrane Database Syst Rev* 2003;(3):CD001190.
11. Williams BR, Nazarians A, Gill MA. A review of rivastigmine: a reversible cholinesterase inhibitor. *Clin Ther* 2003;25(6):1634-53.
12. Corey-Bloom J. Galantamine: a review of its use in Alzheimer's disease and vascular dementia. *Int J Clin Pract* 2003;57(3):219-23.
13. Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. *JAMA* 1994;271(13):992-8.
14. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. *Lancet* 2000;356(9247):2031-6.
15. Passmore AP, Bayer AJ, Steinhagen-Thiessen E. Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials. *J Neurol Sci* 2005;229-30:141-6.
16. Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of rivastigmine in Alzheimer's disease patients with concurrent vascular risk factors. *Eur J Neurol* 2000;7(2):159-69.
17. Kurz AF, Erkinjuntti T, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. *Lancet* 2002; 359(9314):1283-90.
18. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. *N Engl J Med* 2004;351(24): 2509-18.
19. Erkinjuntti T, Kurz A, Small GW, et al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. *Clin Ther* 2003;25(6):1765-82.
20. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. *Drugs Aging* 2004;21(14):931-7.
21. Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. *Neurology* 2004;63(4):651-7.
22. Emre M. Switching cholinesterase inhibitors in patients with Alzheimer's disease. *Int J Clin Pract Suppl* 2002;(127):64-72.
23. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. *Int J Clin Pract Suppl* 2002;(127):45-63.

Cholinesterase inhibitors (ChEIs) can improve and stabilize cognition and function in elderly patients with Alzheimer's disease and other dementias. Switch to another ChEI if one is not effective because the agents' mechanisms differ and response varies among patients. Educate the family and patient not to discontinue these drugs if effective.

BottomLine